Detalles de la búsqueda
1.
Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
PLoS Med
; 21(6): e1004375, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38829821
2.
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.
BMC Pediatr
; 21(1): 117, 2021 03 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33685411
3.
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
Lancet Infect Dis
; 22(9): 1374-1387, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35772449
4.
Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial.
Vaccine X
; 7: 100086, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33681756
5.
Pneumococcal conjugate vaccines PREVenar13 and SynflorIX in sequence or alone in high-risk Indigenous infants (PREV-IX_COMBO): protocol of a randomised controlled trial.
BMJ Open
; 5(1): e007247, 2015 Jan 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-25596202
Resultados
1 -
5
de 5
1
Próxima >
>>